Patent Protected: An Analysis of MilliporeSigma’s Patent in China

Recently, there has been a growing interest in CRISPR gene-editing technologies. CRISPRs are “memories” found in archaea and bacteria that help protect the body against pathogens. Such gene-editing technologies are promising because they are simpler to use than other gene-editing technologies and have the potential to fight cancer, increase crop yield and reverse organ damage. Due to this increasing interest, many companies are patenting CRISPR gene-editing technologies in various jurisdictions. Today, China granted MilliporeSigma a patent for its “chromosomal integration” CRISPR technology.

This grant comes at a particularly interesting time. On April 19 2018, the State Council of China expressed its desire to increase the importation of foreign “innovative” drugs into China. Several proposed mechanisms to achieve this goal included stronger intellectual property protections for such medicines, customs exemptions and making it easier to commercialize such products. Granting a patent for efficient gene-editing technologies seems to be related to China’s broader legal and policy objectives.

With all this in mind, it will be interesting to see the number of patents China grants this year and what subject-matter will be protected by such patents.

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s